AB0192 Can anti-ccp antibody titer predict the use of biologics ?
Background Anti-CCP antibody (ACPA) is widely used for diagnosis of rheumatoid arthritis (RA), and ACPA seropositivity has been known as a factor associated with a poor joint prognosis. However, the importance of ACPA titer, especially its influence for treatment decision, remains unclear. Objective...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A845 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Suppl 3 |
| container_start_page | A845 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 72 |
| creator | Rokutanda, R. Kishimoto, M. Yamaguchi, K. Shimizu, H. Suyama, Y. Ohara, Y. Haji, Y. Min, C. Takeda, A. Matsui, Y. Okada, M. Nishioka, K. |
| description | Background Anti-CCP antibody (ACPA) is widely used for diagnosis of rheumatoid arthritis (RA), and ACPA seropositivity has been known as a factor associated with a poor joint prognosis. However, the importance of ACPA titer, especially its influence for treatment decision, remains unclear. Objectives The purpose of this study is to analyze whether RA patients with higher ACPA titer need biologics more frequently or not. Methods We extracted all the RA patients who underwent ACPA test during the period from February 2012 to October 2012. These patients were divided into three groups based on the value of ACPA, e.g. negative (less than 4.5 U/mL), positive (4.5-100 U/mL), and strong positive (more than 100 U/mL). We retrospectively reviewed all the biologic/non-biologic DMARDs the patients had ever used, and compared the rates of biologics use among three groups. Results The rate of biologic use was significantly lower in negative ACPA group (31.0%) compared to positive ACPA group (55.6%, p |
| doi_str_mv | 10.1136/annrheumdis-2013-eular.2515 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777912431</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008726691</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1651-15451493e451717e39cd57b030802a7e8c9f6e577417f3ea18a4be250dd0f3de3</originalsourceid><addsrcrecordid>eNqVkMtOwzAQRS0EEqXwD5a6TvHEcZyIBSrhUaTykHgsurGcZEJd2qTYiUR3bPhRvoS0QYgtqzszuneudAgZABsC8PBYl6WdYbPMjfN8BtzDZqHt0BcgdkgPgjBqzyHbJT3GGPeCOJT75MC5ebuyCKIeSUZnDGL_6-Mz0SXVZW28LFtth7TK17Q2NVq6spibrKb1DGnjkFYFTU21qF5M5ujpIdkr9MLh0Y_2ydPlxWMy9iZ3V9fJaOKlEArwQAQCgphjKxIk8jjLhUwZZxHztcQoi4sQhZQByIKjhkgHKfqC5TkreI68Twbd35Wt3hp0tZpXjS3bSgVSyhj8gEPrOulcma2cs1iolTVLbdcKmNpQU3-oqQ01taWmNtTatNeljavx_Teq7asKJZdC3T4n6jyaju-nDzfqvPWHnT9dzv9V9A3ZOYYz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777912431</pqid></control><display><type>article</type><title>AB0192 Can anti-ccp antibody titer predict the use of biologics ?</title><source>BMJ Journals - NESLi2</source><creator>Rokutanda, R. ; Kishimoto, M. ; Yamaguchi, K. ; Shimizu, H. ; Suyama, Y. ; Ohara, Y. ; Haji, Y. ; Min, C. ; Takeda, A. ; Matsui, Y. ; Okada, M. ; Nishioka, K.</creator><creatorcontrib>Rokutanda, R. ; Kishimoto, M. ; Yamaguchi, K. ; Shimizu, H. ; Suyama, Y. ; Ohara, Y. ; Haji, Y. ; Min, C. ; Takeda, A. ; Matsui, Y. ; Okada, M. ; Nishioka, K.</creatorcontrib><description>Background Anti-CCP antibody (ACPA) is widely used for diagnosis of rheumatoid arthritis (RA), and ACPA seropositivity has been known as a factor associated with a poor joint prognosis. However, the importance of ACPA titer, especially its influence for treatment decision, remains unclear. Objectives The purpose of this study is to analyze whether RA patients with higher ACPA titer need biologics more frequently or not. Methods We extracted all the RA patients who underwent ACPA test during the period from February 2012 to October 2012. These patients were divided into three groups based on the value of ACPA, e.g. negative (less than 4.5 U/mL), positive (4.5-100 U/mL), and strong positive (more than 100 U/mL). We retrospectively reviewed all the biologic/non-biologic DMARDs the patients had ever used, and compared the rates of biologics use among three groups. Results The rate of biologic use was significantly lower in negative ACPA group (31.0%) compared to positive ACPA group (55.6%, p<0.05) or strong positive ACPA group (67.9%, p<0.05, Table 1). Among ACPA positive patients, strong ACPA group tend to use biologics more frequently. The rate of patients without biologics nor MTX was significantly higher in negative ACPA group (34.5%) than in ACPA positive group (8.3%, p<0.05) or strong positive ACPA group (5.1%, p<0.05). Image/graph Conclusions Not only the ACPA positivity but also high ACPA titer can be predictors for biologics use in RA patients. Disclosure of Interest None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2013-eular.2515</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A845</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A845.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A845.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77343,77374</link.rule.ids></links><search><creatorcontrib>Rokutanda, R.</creatorcontrib><creatorcontrib>Kishimoto, M.</creatorcontrib><creatorcontrib>Yamaguchi, K.</creatorcontrib><creatorcontrib>Shimizu, H.</creatorcontrib><creatorcontrib>Suyama, Y.</creatorcontrib><creatorcontrib>Ohara, Y.</creatorcontrib><creatorcontrib>Haji, Y.</creatorcontrib><creatorcontrib>Min, C.</creatorcontrib><creatorcontrib>Takeda, A.</creatorcontrib><creatorcontrib>Matsui, Y.</creatorcontrib><creatorcontrib>Okada, M.</creatorcontrib><creatorcontrib>Nishioka, K.</creatorcontrib><title>AB0192 Can anti-ccp antibody titer predict the use of biologics ?</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background Anti-CCP antibody (ACPA) is widely used for diagnosis of rheumatoid arthritis (RA), and ACPA seropositivity has been known as a factor associated with a poor joint prognosis. However, the importance of ACPA titer, especially its influence for treatment decision, remains unclear. Objectives The purpose of this study is to analyze whether RA patients with higher ACPA titer need biologics more frequently or not. Methods We extracted all the RA patients who underwent ACPA test during the period from February 2012 to October 2012. These patients were divided into three groups based on the value of ACPA, e.g. negative (less than 4.5 U/mL), positive (4.5-100 U/mL), and strong positive (more than 100 U/mL). We retrospectively reviewed all the biologic/non-biologic DMARDs the patients had ever used, and compared the rates of biologics use among three groups. Results The rate of biologic use was significantly lower in negative ACPA group (31.0%) compared to positive ACPA group (55.6%, p<0.05) or strong positive ACPA group (67.9%, p<0.05, Table 1). Among ACPA positive patients, strong ACPA group tend to use biologics more frequently. The rate of patients without biologics nor MTX was significantly higher in negative ACPA group (34.5%) than in ACPA positive group (8.3%, p<0.05) or strong positive ACPA group (5.1%, p<0.05). Image/graph Conclusions Not only the ACPA positivity but also high ACPA titer can be predictors for biologics use in RA patients. Disclosure of Interest None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkMtOwzAQRS0EEqXwD5a6TvHEcZyIBSrhUaTykHgsurGcZEJd2qTYiUR3bPhRvoS0QYgtqzszuneudAgZABsC8PBYl6WdYbPMjfN8BtzDZqHt0BcgdkgPgjBqzyHbJT3GGPeCOJT75MC5ebuyCKIeSUZnDGL_6-Mz0SXVZW28LFtth7TK17Q2NVq6spibrKb1DGnjkFYFTU21qF5M5ujpIdkr9MLh0Y_2ydPlxWMy9iZ3V9fJaOKlEArwQAQCgphjKxIk8jjLhUwZZxHztcQoi4sQhZQByIKjhkgHKfqC5TkreI68Twbd35Wt3hp0tZpXjS3bSgVSyhj8gEPrOulcma2cs1iolTVLbdcKmNpQU3-oqQ01taWmNtTatNeljavx_Teq7asKJZdC3T4n6jyaju-nDzfqvPWHnT9dzv9V9A3ZOYYz</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Rokutanda, R.</creator><creator>Kishimoto, M.</creator><creator>Yamaguchi, K.</creator><creator>Shimizu, H.</creator><creator>Suyama, Y.</creator><creator>Ohara, Y.</creator><creator>Haji, Y.</creator><creator>Min, C.</creator><creator>Takeda, A.</creator><creator>Matsui, Y.</creator><creator>Okada, M.</creator><creator>Nishioka, K.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>AB0192 Can anti-ccp antibody titer predict the use of biologics ?</title><author>Rokutanda, R. ; Kishimoto, M. ; Yamaguchi, K. ; Shimizu, H. ; Suyama, Y. ; Ohara, Y. ; Haji, Y. ; Min, C. ; Takeda, A. ; Matsui, Y. ; Okada, M. ; Nishioka, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1651-15451493e451717e39cd57b030802a7e8c9f6e577417f3ea18a4be250dd0f3de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rokutanda, R.</creatorcontrib><creatorcontrib>Kishimoto, M.</creatorcontrib><creatorcontrib>Yamaguchi, K.</creatorcontrib><creatorcontrib>Shimizu, H.</creatorcontrib><creatorcontrib>Suyama, Y.</creatorcontrib><creatorcontrib>Ohara, Y.</creatorcontrib><creatorcontrib>Haji, Y.</creatorcontrib><creatorcontrib>Min, C.</creatorcontrib><creatorcontrib>Takeda, A.</creatorcontrib><creatorcontrib>Matsui, Y.</creatorcontrib><creatorcontrib>Okada, M.</creatorcontrib><creatorcontrib>Nishioka, K.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rokutanda, R.</au><au>Kishimoto, M.</au><au>Yamaguchi, K.</au><au>Shimizu, H.</au><au>Suyama, Y.</au><au>Ohara, Y.</au><au>Haji, Y.</au><au>Min, C.</au><au>Takeda, A.</au><au>Matsui, Y.</au><au>Okada, M.</au><au>Nishioka, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0192 Can anti-ccp antibody titer predict the use of biologics ?</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A845</spage><pages>A845-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Anti-CCP antibody (ACPA) is widely used for diagnosis of rheumatoid arthritis (RA), and ACPA seropositivity has been known as a factor associated with a poor joint prognosis. However, the importance of ACPA titer, especially its influence for treatment decision, remains unclear. Objectives The purpose of this study is to analyze whether RA patients with higher ACPA titer need biologics more frequently or not. Methods We extracted all the RA patients who underwent ACPA test during the period from February 2012 to October 2012. These patients were divided into three groups based on the value of ACPA, e.g. negative (less than 4.5 U/mL), positive (4.5-100 U/mL), and strong positive (more than 100 U/mL). We retrospectively reviewed all the biologic/non-biologic DMARDs the patients had ever used, and compared the rates of biologics use among three groups. Results The rate of biologic use was significantly lower in negative ACPA group (31.0%) compared to positive ACPA group (55.6%, p<0.05) or strong positive ACPA group (67.9%, p<0.05, Table 1). Among ACPA positive patients, strong ACPA group tend to use biologics more frequently. The rate of patients without biologics nor MTX was significantly higher in negative ACPA group (34.5%) than in ACPA positive group (8.3%, p<0.05) or strong positive ACPA group (5.1%, p<0.05). Image/graph Conclusions Not only the ACPA positivity but also high ACPA titer can be predictors for biologics use in RA patients. Disclosure of Interest None Declared</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2013-eular.2515</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A845 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_journals_1777912431 |
| source | BMJ Journals - NESLi2 |
| title | AB0192 Can anti-ccp antibody titer predict the use of biologics ? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A38%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0192%E2%80%85Can%20anti-ccp%20antibody%20titer%20predict%20the%20use%20of%20biologics%20?&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Rokutanda,%20R.&rft.date=2013-06&rft.volume=72&rft.issue=Suppl%203&rft.spage=A845&rft.pages=A845-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2013-eular.2515&rft_dat=%3Cproquest_cross%3E4008726691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777912431&rft_id=info:pmid/&rfr_iscdi=true |